RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study

URN to cite this document:: urn:nbn:de:bvb:355-epub-293079
DOI to cite this document:: 10.5283/epub.29307

Beier, Christoph P. ; Schmid, Christina ; Gorlia, Thierry ; Kleinletzenberger, Christine ; Beier, Dagmar ; Grauer, Oliver ; Steinbrecher, Andreas ; Hirschmann, Birgit ; Brawanski, Alexander ; Dietmaier, Christopher ; Jauch-Worley, Tanja ; Kölbl, Oliver ; Pietsch, Torsten ; Proescholdt, Martin A. ; Rümmele, Petra ; Muigg, Armin ; Stockhammer, Günther ; Hegi, Monika

; Bogdahn, Ulrich ; Hau, Peter

Preview

PDF
(233kB)

Date of publication of this fulltext: 16 Jan 2014 11:37

Alternative links to fulltext:Pubmed DOI

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background: Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for. Methods: In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx (TM), PEG-Dox) and prolonged administration of Temozolomide in addition to radiotherapy was investigated in 63 patients with newly diagnosed glioblastoma. In phase-I, ...